P. Bady

Discipline

Psychologie (1)

Discipline

Sciences de l'information et de la communication (1)

Type de document

Articles (16)

Type de document

Autres (1)

Co-auteur

Auteur

Date

Date

Source

Source

Mot-clé

Treatment (10) Patients (10) Methylation (10) Methylation (10) Patients (10) gène (8) ADN (8) cancer (8) Cancer (8) Human beings (8) Expression (8) DNA (8) Cancer (8) thérapie (7) analyse (7) Therapeutics (7) Brain (7) Analysis (7) cerveau (7) effet (6) survie (6) Tumors (6) Survival (6) association (5) adulte (5) Genes (5) Social groups (5) Forecasting (5) Example (5) Cells (5)

Documents écrit par P. Bady (16) | parle de P. Bady (1)

BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
A. Tancredi et al. (13 déc. 2022)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome-including in elderly patients.
P. Bady et al. (24 mars 2022)
BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.
O. Gusyatiner et al. (1 oct. 2021)
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice.
C. Cudalbu et al. (4 août 2021)
Metabolic and transcriptomic profiles of glioblastoma invasion revealed by comparisons between patients and corresponding orthotopic xenografts in mice
C. Cudalbu et al. (1 juil. 2021)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
P. Bady et al.
Ubiquitin Specific Peptidase 15 (USP15) suppresses glioblastoma cell growth via stabilization of HECTD1 E3 ligase attenuating WNT pathway activity.
M. Oikonomaki et al. (15 déc. 2017)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
W. Wick et al. (1 oct. 2016)
Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
M. Weller et al. (22 mars 2016)
Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors.
P. Bady et al. (2016)
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma.
S. Kurscheid et al. (2015)
Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact.
P. Sathyan et al. (2015)
Genome-wide DNA methylation detection by MethylCap-seq and Infinium HumanMethylation450 BeadChips: an independent large-scale comparison.
T. De Meyer et al. (2015)
Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2013)
Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
M.E. Hegi et al. (2012)
MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
P. Bady et al. (2012)

Lao She : La cage entrebâillée
Paul Bady et al. (1986)